Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States

Preventive Medicine

Volumn 123, Issue , 2019, Pages 316-323

  Islami, Farhad ^a   Fedewa, Stacey A ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

Adenocarcinoma; Cervical cancer; Human papillomavirus; Screening; Squamous cell carcinoma

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ASIAN; BLACK PERSON; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; ETHNICITY; FEMALE; HISPANIC; HISTOLOGY; HUMAN; HYSTERECTOMY; PACIFIC ISLANDER; PRIORITY JOURNAL; RACE; TREND STUDY; UNITED STATES; UTERINE CERVIX CANCER; ADENOCARCINOMA; AFRICAN AMERICAN; AGE DISTRIBUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER REGISTRY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; ETHNIC GROUP; INCIDENCE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS; TUMOR INVASION; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; HYSTERECTOMY; INCIDENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 85064476598     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2019.04.010     Document Type: Article

References (39)

1. Alber, J.M., Brewer, N.T., Melvin, C., Yackle, A., Smith, J.S., Ko, L.K., et al. Reducing overuse of cervical cancer screening: a systematic review. Prev. Med. 116 (2018), 51–59.
2. Baldur-Felskov, B., Munk, C., Nielsen, T.S., Dehlendorff, C., Kirschner, B., Junge, J., et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012. Cancer Causes Control 26:8 (2015), 1105–1116.
3. Beavis, A.L., Gravitt, P.E., Rositch, A.F., Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer 123:6 (2017), 1044–1050.
4. Bray, F., Carstensen, B., Moller, H., Zappa, M., Zakelj, M.P., Lawrence, G., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol. Biomark. Prev. 14:9 (2005), 2191–2199.
5. Castle, P.E., Kinney, W.K., Cheung, L.C., Gage, J.C., Fetterman, B., Poitras, N.E., et al. Why does cervical cancer occur in a state-of-the-art screening program?. Gynecol. Oncol. 146:3 (2017), 546–553.
6. CDC/NCI, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: USCS Incidence Analytic Database – 1998–2015. 2017, United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (Based on the November 2017 submission).
7. Clarke, M.A., Fetterman, B., Cheung, L.C., Wentzensen, N., Gage, J.C., Katki, H.A., et al. Epidemiologic evidence that excess body weight increases risk of cervical cancer by decreased detection of precancer. J. Clin. Oncol. 36:12 (2018), 1184–1191.
8. Crosbie, E.J., Einstein, M.H., Franceschi, S., Kitchener, H.C., Human papillomavirus and cervical cancer. Lancet 382:9895 (2013), 889–899.
9. Doubeni, C.A., Gabler, N.B., Wheeler, C.M., McCarthy, A.M., Castle, P.E., Halm, E.A., et al. Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR Consortium. CA Cancer J. Clin. 68:3 (2018), 199–216.
10. Gradissimo, A., Burk, R.D., Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert. Rev. Mol. Diagn. 17:4 (2017), 379–391.
11. Guo, F., Cofie, L.E., Berenson, A.B., Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am. J. Prev. Med. 55:2 (2018), 197–204.
12. Hales, C.M., Fryar, C.D., Carroll, M.D., Freedman, D.S., Ogden, C.L., Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. JAMA 319:16 (2018), 1723–1725.
13. Jemal, A., Simard, E.P., Dorell, C., Noone, A.M., Markowitz, L.E., Kohler, B., et al. Annual Report to the Nation on the Status of Cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J. Natl. Cancer Inst. 105:3 (2013), 175–201.
14. Joste, N.E., Ronnett, B.M., Hunt, W.C., Pearse, A., Langsfeld, E., Leete, T., et al. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol. Biomark. Prev. 24:1 (2015), 230–240.
15. Katki, H.A., Kinney, W.K., Fetterman, B., Lorey, T., Poitras, N.E., Cheung, L., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12:7 (2011), 663–672.
16. Lonnberg, S., Hansen, B.T., Haldorsen, T., Campbell, S., Schee, K., Nygard, M., Cervical cancer prevented by screening: long-term incidence trends by morphology in Norway. Int. J. Cancer 137:7 (2015), 1758–1764.
17. Luttmer, R., De Strooper, L.M., Steenbergen, R.D., Berkhof, J., Snijders, P.J., Heideman, D.A., et al. Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Expert. Rev. Mol. Diagn. 16:9 (2016), 961–974.
18. Markowitz, L.E., Liu, G., Hariri, S., Steinau, M., Dunne, E.F., Unger, E.R., Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics, 137(3), 2016, e20151968.
19. Melnikow, J., Henderson, J.T., Burda, B.U., Senger, C.A., Durbin, S., Weyrich, M.S., Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force. JAMA 320:7 (2018), 687–705.
20. Mirabello, L., Yeager, M., Cullen, M., Boland, J.F., Chen, Z., Wentzensen, N., et al. HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women. J. Natl. Cancer Inst., 108(9), 2016.
21. National Center for Health Statistics, National Health Interview Survey. NHIS data, questionnaires and related documentation. Available from: https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm, 2018. (Accessed 31 August 2018)
22. Orumaa, M., Leinonen, M.K., Campbell, S., Moller, B., Myklebust, T.A., Nygard, M., Recent increase in incidence of cervical precancerous lesions in Norway: nationwide study from 1992 to 2016. Int. J. Cancer, 2019, 10.1002/ijc.32195 (Epub ahead of print).
23. Phipps, A.I., Buist, D.S., Validation of self-reported history of hysterectomy and oophorectomy among women in an integrated group practice setting. Menopause 16:3 (2009), 576–581.
24. Ronco, G., Dillner, J., Elfstrom, K.M., Tunesi, S., Snijders, P.J., Arbyn, M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:9916 (2014), 524–532.
25. Ryser, M.D., Rositch, A., Gravitt, P.E., Modeling of US human papillomavirus (HPV) seroprevalence by age and sexual behavior indicates an increasing trend of HPV infection following the sexual revolution. J. Infect. Dis. 216:5 (2017), 604–611.
26. Saslow, D., Runowicz, C.D., Solomon, D., Moscicki, A.B., Smith, R.A., Eyre, H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52:6 (2002), 342–362.
27. Saslow, D., Castle, P.E., Cox, J.T., Davey, D.D., Einstein, M.H., Ferris, D.G., et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin. 57:1 (2007), 7–28.
28. Siegel, R.L., Devesa, S.S., Cokkinides, V., Ma, J., Jemal, A., State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. Cancer Epidemiol. Biomark. Prev. 22:1 (2013), 25–31.
29. Smith, R.A., von Eschenbach, A.C., Wender, R., Levin, B., Byers, T., Rothenberger, D., et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001—testing for early lung cancer detection. CA Cancer J. Clin. 51:1 (2001), 38–75 (quiz 77-80).
30. Smith, R.A., Andrews, K.S., Brooks, D., Fedewa, S.A., Manassaram-Baptiste, D., Saslow, D., et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 68:4 (2018), 297–316.
31. U.S. Preventive Services Task Force, Curry, S.J., Krist, A.H., Owens, D.K., Barry, M.J., Caughey, A.B., et al. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. JAMA 320:7 (2018), 674–686.
32. Van Dyne, E.A., Henley, S.J., Saraiya, M., Thomas, C.C., Markowitz, L.E., Benard, V.B., Trends in human papillomavirus-associated cancers - United States, 1999–2015. MMWR Morb. Mortal. Wkly Rep. 67:33 (2018), 918–924.
33. Walker, T.Y., Elam-Evans, L.D., Yankey, D., Markowitz, L.E., Williams, C.L., Mbaeyi, S.A., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2017. MMWR Morb. Mortal. Wkly Rep. 67:33 (2018), 909–917.
34. Wang, S.S., Sherman, M.E., Hildesheim, A., Lacey, J.V. Jr., Devesa, S., Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:5 (2004), 1035–1044.
35. Watson, M., Benard, V., King, J., Crawford, A., Saraiya, M., National assessment of HPV and Pap tests: changes in cervical cancer screening, National Health Interview Survey. Prev. Med. 100 (2017), 243–247.
36. White, A., Thompson, T.D., White, M.C., Sabatino, S.A., de Moor, J., Doria-Rose, P.V., et al. Cancer screening test use - United States, 2015. MMWR Morb. Mortal. Wkly Rep. 66:8 (2017), 201–206.
37. Zhao, C., Crothers, B.A., Tabatabai, Z.L., Li, Z., Ghofrani, M., Souers, R.J., et al. False-negative interpretation of adenocarcinoma in situ in the College of American Pathologists gynecologic PAP education program. Arch. Pathol. Lab. Med. 141:5 (2017), 666–670.
38. Zheng, T., Holford, T.R., Ma, Z., Chen, Y., Liu, W., Ward, B.A., et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int. J. Epidemiol. 25:2 (1996), 252–258.
39. Zhu, C., Bassig, B.A., Zhang, Y., Shi, K., Boyle, P., Li, N., et al. A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA. Eur. J. Cancer Prev. 24:3 (2015), 240–244.